The biotech scorecard for the Q3: 12 make-or-break events to watch

The biotech scorecard for the Q3: 12 make-or-break events to watch

Biotech's big third quarter is drawing to a close

(JENNIFER KEEFE/STAT)

TG Therapeutics issued what you might describe as a quizzical update to its ongoing cancer trial yesterday, which was reason to update our emoji-fluent biotech scorecard with an appropriately quizzical figure.

And speaking of that scorecard, it is very nearly full after a quarter of news, surprising and otherwise, that shifted billions of dollars in market value. Here's what's left for September:

• Esperion Therapeutics is going to learn whether its ambitious plan to disrupt the market for cholesterol drugs has legs when a Phase 3 trial reads out this month.
• Insmed is going to find out what the FDA thinks of its inhalable treatment for a lung infection by Sept. 28, when the agency will decide whether to approve the drug.
• And Regeneron Pharmaceuticals has a shot at winning an early FDA approval for its immuno-oncology drug, giving it a shot to compete in a crowded market ruled by Merck and Bristol-Myers Squibb.